Tiapride in Parkinson's disease

New insights into the cause of Parkinson's disease.

Neurology·1992

Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group.

Annals of neurology·1992

Fronto-striatal cognitive deficits at different stages of Parkinson's disease.

Brain : a journal of neurology·1992

The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease.

Journal of neurology, neurosurgery, and psychiatry·1992

"Isolated" postinfectious myoclonus.

Journal of neurology, neurosurgery, and psychiatry·1992

Striatal neuropeptide levels in Parkinson's disease patients.

Neuroscience letters·1992

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Mutation-Induced Pocket Deactivation: How Ser353/Pro245 Alters KCa2.2 vs. KCa3.1 Ligand Selectivity.

Archiv der Pharmazie·2026

A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease.

Science translational medicine·2026

Efficacy of DPP-4 Inhibitors on Seated and Ambulatory Blood Pressure in Type 2 Diabetes Mellitus.

Diabetes, obesity & metabolism·2026

Ameliorative Effects of Spirulina platensis Protein Hydrolysate on Oxidative Stress and Dyslipidemia in Model Animal.

Foods (Basel, Switzerland)·2026

Comparison of essential drug lists: concordance, differences, and the need for core lists in times of crisis.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment.

JAMA network open·2026

Related Experiment Videos

Tiapride in Parkinson's disease

Related Concept Videos

New insights into the cause of Parkinson's disease.

Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group.

Fronto-striatal cognitive deficits at different stages of Parkinson's disease.

The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease.

"Isolated" postinfectious myoclonus.

Striatal neuropeptide levels in Parkinson's disease patients.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Mutation-Induced Pocket Deactivation: How Ser353/Pro245 Alters K<sub>Ca</sub>2.2 vs. K<sub>Ca</sub>3.1 Ligand Selectivity.

A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease.

Efficacy of DPP-4 Inhibitors on Seated and Ambulatory Blood Pressure in Type 2 Diabetes Mellitus.

Ameliorative Effects of <i>Spirulina platensis</i> Protein Hydrolysate on Oxidative Stress and Dyslipidemia in Model Animal.

Comparison of essential drug lists: concordance, differences, and the need for core lists in times of crisis.

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment.

Related Experiment Videos

Tiapride in Parkinson's disease

Related Concept Videos

Related Articles